Key Highlights
- Arcturus Therapeutics topped Earnings expectations in its second-quarter 2026 results.
- Enrollment in its Phase 2 study of ARCT-032 for cystic fibrosis remained on schedule during the quarter.
- The company develops messenger-RNA and self-amplifying-RNA medicines and vaccines, including the partnered Kostaive COVID vaccine.
- As a company with a mix of partnered and proprietary programs, its value depends on pipeline progress, partnerships, and funding.
Arcturus Therapeutics (NASDAQ:ARCT) is a biopharmaceutical company developing messenger-RNA and self-amplifying-RNA medicines and vaccines, using its proprietary RNA and lipid-nanoparticle-delivery technologies. No last-closing price move has been supplied for this ticker, so no directional stock-price claim is made here.
Its work spans infectious-disease vaccines, including a self-amplifying-RNA COVID Vaccine known as Kostaive developed with a partner, and rare-disease programs such as candidates for cystic fibrosis and other conditions. As a company with a mix of partnered and proprietary programs and limited product revenue, its value depends on its pipeline, partnerships, and funding.
Latest Developments
In its second-quarter 2026 results, Arcturus topped earnings expectations and reported pipeline progress, including that enrollment in its Phase 2 study of ARCT-032 for cystic fibrosis remained on schedule, alongside its vaccine collaborations. Investors should confirm the latest Revenue and its sources, pipeline and clinical progress including for ARCT-032, net loss and cash position, and guidance directly from SEC filings.
Financial and Business Position
Arcturus's Investment case rests on its RNA and delivery technologies, its pipeline of rare-disease and vaccine programs, and its partnerships, which can provide revenue and validation, balanced against ongoing losses and the clinical and regulatory risks of drug development. Investors should watch revenue and its sources, clinical progress particularly ARCT-032, net loss and cash burn, and the Economics of its partnerships.
Stock-Market Context
No last-closing price data has been supplied for ARCT, so this article makes no directional stock-price claim. The stock is a speculative clinical-stage and partnered biopharmaceutical company whose shares can be volatile around clinical data, regulatory and Partnership news, and financings, trading on the potential of its RNA-medicines pipeline rather than on established profitability.
What Investors Should Watch
Watch revenue and its sources, clinical progress across its pipeline particularly the ARCT-032 cystic-fibrosis program and its vaccine collaborations, net loss and cash burn, the cash position, and the economics and progress of its partnerships. Positive clinical and regulatory advancement backed by adequate funding and valuable partnerships would be the most direct factors that could make the next move bigger.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...